1 Exploring the Feasibility of Using Real-World Data from a Large Clinical Data Research Network

2 to Simulate Clinical Trials of Alzheimer's Disease

- 3 Zhaoyi Chen^{1*}, Hansi Zhang^{1*}, Yi Guo¹, Thomas J George², Mattia Prosperi³, William R Hogan¹, Zhe
- 4 He⁴, Elizabeth A Shenkman¹, Fei Wang⁵, Jiang Bian¹
- 5
- ⁶ ¹Health Outcomes & Biomedical Informatics, University of Florida, Gainesville, Florida, USA
- ⁷²Hematology & Oncology, Department of Medicine, College of Medicine, University of Florida,
- 8 Gainesville, Florida, USA
- 9 ³Department of Epidemiology, College of Public Health and Health Professions & College of
- 10 Medicine, University of Florida, Gainesville, Florida, USA
- 11 ⁴School of Information, Florida State University, Tallahassee, Florida, USA
- ⁵Department of Healthcare Policy and Research, Cornell University, New York, USA
- 13
- 14 Corresponding author: Jiang Bian, PhD
- 15 College of Medicine
- 16 University of Florida
- 17 2197 Mowry Road Suite 122
- 18 PO Box 100177
- 19 Gainesville, FL 32610-0177
- 20 <u>bianjiang@ufl.edu</u>
- 21 352 273-8878
- 22
- 23 Keywords: trial simulation, real-world data, Alzheimer's Disease

24 ABSTRACT

25 In this study, we explored the feasibility of using real-world data (RWD) from a large clinical research network to simulate real-world clinical trials of Alzheimer's disease (AD). The target trial 26 27 (i.e., NCT00478205) is a Phase III double-blind, parallel-group trial that compared the 23 mg 28 donepezil sustained release with the 10 mg donepezil immediate release formulation in patients 29 with moderate to severe AD. We followed the target trial's study protocol to identify the study 30 population, treatment regimen assignments, and outcome assessments, and to set up a number of 31 different simulation scenarios and parameters. We considered two main scenarios: (1) a one-arm 32 simulation: simulating a standard-of-care arm that can serve as an external control arm; and (2) a 33 two-arm simulation: simulating both intervention and control arms with proper patient matching 34 algorithms for comparative effectiveness analysis. In the two-arm simulation scenario, we used 35 propensity score matching controlling for baseline characteristics to simulate the randomization 36 process. In the two-arm simulation, higher SAE rates were observed in the simulated trials than the 37 rates reported in original trial, and a higher SAE rate was observed in the 23mg arm than the 10 mg 38 standard-of-care arm. In the one-arm simulation scenario, similar estimates of SAE rates were 39 observed when proportional sampling was used to control demographic variables. In conclusion, 40 trial simulation using RWD is feasible in this example of AD trial in terms of safety evaluation. Trial 41 simulation using RWD could be a valuable tool for post-market comparative effectiveness studies 42 and for informing future trials' design. Nevertheless, such approach may be limited, for example, 43 by the availability of RWD that matches the target trials of interest, and further investigations are 44 warranted.

45 Introduction

46	Clinical trials, especially randomized controlled trials (RCTs), are critical in the drug discovery and
47	development process to assess the efficacy and safety of the new treatment. ¹ While the rigorously
48	controlled conditions of clinical trials can reduce bias and improve the internal validity of the study
49	results, they also come with the drawbacks of high financial costs and long execution time. ² For
50	example, the total cost of developing an Alzheimer's disease (AD) drug was estimated at \$5.6 billion
51	with a timeline of 13 years from the preclinical studies to approval by the Food and Drug
52	Administration (FDA). ³ Nevertheless, no effective drugs yet have been developed for either
53	treatment or prevention of AD thus far. Strategies that can accelerate the drug development process
54	and reduce costs will not only be of interest to pharmaceutical companies but also ultimately benefit
55	the patients.
56	
57	Clinical trial simulation (CTS) is a valuable to assess the feasibility, investigate assumptions, and
57 58	Clinical trial simulation (CTS) is a valuable to assess the feasibility, investigate assumptions, and optimize study design before conducting the actual trials. ^{4,5} For example, Romero <i>et al.</i> conducted a
58	optimize study design before conducting the actual trials. ^{4,5} For example, Romero <i>et al.</i> conducted a
58 59	optimize study design before conducting the actual trials. ^{4,5} For example, Romero <i>et al.</i> conducted a CTS study to explore several design scenarios comparing the effects of donepezil with placebo. ⁶
58 59 60	optimize study design before conducting the actual trials. ^{4,5} For example, Romero <i>et al.</i> conducted a CTS study to explore several design scenarios comparing the effects of donepezil with placebo. ⁶ Traditionally, CTS studies use virtual cohorts generated based on pharmacokinetics /
58 59 60 61	optimize study design before conducting the actual trials. ^{4,5} For example, Romero <i>et al.</i> conducted a CTS study to explore several design scenarios comparing the effects of donepezil with placebo. ⁶ Traditionally, CTS studies use virtual cohorts generated based on pharmacokinetics / pharmacodynamics models of the therapeutic agents, so these cohorts do not necessarily reflect the
5859606162	optimize study design before conducting the actual trials. ^{4,5} For example, Romero <i>et al.</i> conducted a CTS study to explore several design scenarios comparing the effects of donepezil with placebo. ⁶ Traditionally, CTS studies use virtual cohorts generated based on pharmacokinetics / pharmacodynamics models of the therapeutic agents, so these cohorts do not necessarily reflect the patients who will use the drugs in the real world. More recently, the trial emulation (i.e., "the target
 58 59 60 61 62 63 	optimize study design before conducting the actual trials. ^{4,5} For example, Romero <i>et al.</i> conducted a CTS study to explore several design scenarios comparing the effects of donepezil with placebo. ⁶ Traditionally, CTS studies use virtual cohorts generated based on pharmacokinetics / pharmacodynamics models of the therapeutic agents, so these cohorts do not necessarily reflect the patients who will use the drugs in the real world. More recently, the trial emulation (i.e., "the target trial") framework—emulating hypothetical trials to establish the estimation of the casual effects, has
 58 59 60 61 62 63 64 	optimize study design before conducting the actual trials. ^{4,5} For example, Romero <i>et al.</i> conducted a CTS study to explore several design scenarios comparing the effects of donepezil with placebo. ⁶ Traditionally, CTS studies use virtual cohorts generated based on pharmacokinetics / pharmacodynamics models of the therapeutic agents, so these cohorts do not necessarily reflect the patients who will use the drugs in the real world. More recently, the trial emulation (i.e., "the target trial") framework—emulating hypothetical trials to establish the estimation of the casual effects, has attracted significant attention. ⁷ For example, Danaei <i>et al.</i> emulated a hypothetical RCT used

68	unbiased initiation of exposures and eventually to reach an unbiased estimation of the casual			
69	relationship. Combining the ideas from CTS and trial emulation, a simulation study using real-			
70	world data (RWD) to test different assumptions (e.g., different drop-out rates) and trial designs (e.g.,			
71	different eligibility criteria) could provide insights on the effectiveness and safety of the treatments			
72	to be developed in a real-world setting that reflect the patient populations who will actually use the			
73	treatment.			
74				
75	In this study, we explored the feasibility of using RWD from the OneFlorida Clinical Research			
76	Consortium—a clinical data research network funded by the Patient-Centered Outcomes Research			
77	Institute (PCORI) contributing to the national Patient-Centered Clinical Research Network			
78	(PCORnet)—to simulate a real-world AD RCT as a use case. We considered two main scenarios: (1)			
79	a one-arm simulation: simulating a standard-of-care arm that can serve as an external control arm;			
80	and (2) a two-arm simulation: simulating both intervention and control arms with proper patient			
81	matching algorithms for comparative effectiveness analysis.			
82				
83	Results			
84	Computability of eligibility criteria in the original trial (i.e., NCT00478205)			
85	In total, there are 36 eligibility criteria in trial NCT00478205, where 17 are inclusion and 19 are			
86	exclusion criteria. However, not all criteria are computable against the OneFlorida patient database:			
87	(1) 11 are not computable, and (2) 7 are partially computable (i.e., a part of the criterion is not			
88	computable). Similar to what we have found in our prior study ¹¹ , the common reasons for not			
89	computable criteria are (1) data elements needed for the criterion do not exist in the source database			
90	(e.g., "A cranial image is required, with no evidence of focal brain disease that would account for dementia."),			

91 or (2) the criterion asked for subjective information either from the patient (e.g., "Patients who are 92 unwilling or unable to fulfill the requirements of the study.") or the investigator (e.g., ""Clinical laboratory 93 values must be within normal limits or, if abnormal, must be judged not clinically significant by the 94 investigator."). When a criterion is not computable, we consider all candidate patients met that 95 criterion (e.g., they are all willing and able to "fulfill the requirements of the study"). 96 97 Characteristics of the target, study, and trial not eligible populations from OneFlorida 98 Overall, a total of 90 and 2,048 patients were identified as the effective target populations in 99 OneFlorida for the 23 mg arm and 10 mg arm, respectively. Among them, 38 and 782 met the 100 eligibility criteria of the original target RCT for the two arms, respectively. *Table 2* shows the 101 demographic characteristics and SAE statistics of the original trial population as well as the effective 102 target population (TP), study population (SP), and trial not eligible population (NEP) from 103 OneFlorida. 104 105 For demographic characteristics, relative to the target RCT population, we observed a large 106 difference in race in our OneFlorida population (all p-values of race group comparisons were 107 smaller than 0.05). OneFlorida had more Hispanics (10.5% - 24.6% vs. 5.5% - 7%) and Blacks (10.5% -108 20.1% vs. 1.9% - 2.3%), but less Whites (35.8% - 73.1% vs. 73.5% - 73.5%) or Asian/Pacific islanders 109 (0% - 1.4% vs. 16.7% - 18.5%). The age distributions were similar across all populations. For clinical 110 variables, we calculated the Charlson Comorbidity Index (CCI) of the various populations from 111 OneFlorida. Smaller CCIs were observed in the SP compared with the TP for both arms (p<0.05), 112 and a smaller CCI was observed in the 23mg arm compared with the 10mg arm (p<0.05). Our

113 primary outcomes of interest in this analysis were SAEs. Thus, we calculated the mean SAE (i.e., the

114	average number of SAEs per patient) and the number of patients who had more than 1 SAE during
115	the study period. For both 23mg and 10mg arms, the mean SAE and the number of patients with
116	SAEs were the largest in the TP, followed by the SP, and then the original trial. Consistent with the
117	original trial, populations derived from the OneFlorida data in the 23mg arm have higher numbers
118	of mean SAE and more patients with SAE compared with the 10mg arm.

119

120 Standard-of-care control arm (i.e., one-arm) simulation

121 We first simulated the control arm of the original trial (i.e., the 10mg stand-of-care arm). Table 3 122 displays the demographics and SAE outcomes in the simulated control arms. Here, we reported the 123 mean value and 95% confidence interval of all 1,000 bootstrap samples. Two different sampling 124 approaches were used: (1) random sampling, and (2) proportional sampling accounting for race 125 distribution. When using the random sampling approach, compared with the control arm in the 126 original trial, higher mean SAE and SAE rates were observed, in addition to discrepancies in 127 demographic variables. When using proportional sampling, the results were closer and more 128 consistent with the original trial. Notably, the SAE rates in the simulated control were similar to the 129 SAE rates from the original control (8.9% vs. 8.3%), and a z-score test for population proportion had 130 a p-value of 0.75, suggesting there were no significant differences between the two SAE rates. In 131 addition to SAE rates and mean SAE, we also explored the SAE event rates in the simulated control 132 arms stratified by the SAE category reported in the original trial. Compared with the control arm in 133 the original trial, the simulated control arms have larger SAE rates in most categories.

134

135 Two-arm trial simulation

136 Because the proportional sampling had better performance in the one-arm simulation, we used this 137 sampling strategy in the two-arm simulation to match the race distribution, and tested two scenarios 138 of different matching ratios (i.e., proportional 1:1 matching and proportional 1:3 matching). 139 However, since there is no Asian/Pacific in our study population who used 23mg donepezil, all 140 Asians in the original trial and the simulated control arm were grouped into "other", and the sample 141 size of the 23mg arm was set at 30 (because of the limited number of 23mg patients in the 142 OneFlorida data). Table 4 shows our two-arm simulation results, where we show the average and 143 95% CI of all variables for the simulation arms across all 1,000 bootstrap samples. In both matching 144 scenarios, the mean SAE and SAE rates were higher in the 23mg arm than in the 10mg arm, which is 145 consistent with the original trial. However, the variance for both SAE outcomes for the 10mg arm 146 are higher in the 1:1 matching scenario than in the 1:3 matching scenario, as the sample size for the 147 10mg arm in the 1:3 matching scenario is much bigger. Because of the sample size difference, 148 estimates from the 1:3 matching scenario should be more reliable. Consistent with the original trial, 149 patients in the 23mg arm have higher event rates in most of the SAE categories compared to the 150 patients in the 10mg arm. Note that we observed no SAE events in several categories in our 151 simulation, especially in the 23mg arm, due to the limited sample size.

152

Finally, we conducted an additional experiment to simulate patients who withdrew from the trial. In the original trial, among the 963 and 471 patients from each arm, 296 (30%) and 87 (18%) patients discontinued the study for various of reason, respectively. Among the dropouts, 182 and 39 patients discontinued due to AEs. We simulated the dropouts by (1) randomly removing 18% in the 10mg group and 30% in the 23mg in our simulations; and (2) removing the patient after his or her first AE using the same proportion as the original trial (i.e., due to small sample size, we did not simulate

159	this scenario for the two-arm simulation). The results are displayed in Supplementary Table 3 and
160	Supplementary Table 4. For the random dropout scenario, similar SAE rates and smaller mean SAE
161	were observed across all scenarios. For example, in the control arm of the random dropout scenario,
162	mean SAE decreased from 0.64 to 0.19 and 0.23 in the two different dropout simulations, while in
163	the two-arm simulation, the mean SAE for the 10mg arm were 0.22 and 0.19 in the two scenarios,
164	both were much lower than simulations without dropout (0.46 and 0.47 respectively). However, the
165	effects of dropout were mostly observed in control arms, the SAE rates and mean SAE remained the
166	same for the 23mg arm before and after dropout simulation. In the AE-based dropout scenario, both
167	smaller SAE rates and smaller mean SAE were observed: the SAE rates decreased from 8.8% to 7.3%
168	and the mean SAE decreased from 0.64 to 0.23, where the mean SAE estimate was closer to the
169	original trial results.

170

171 DISCUSSION

In this work, we simulated an AD RCT utilizing RWD from the OneFlorida network—a large clinical 172 173 data research network, considering three different simulation scenarios. In the one-arm simulation 174 scenario, we attempted to simulate an external control arm for the original trial. We demonstrated 175 that we could achieve similar estimate of SAE rates as the original trial when proportional sampling 176 accounting for race distribution was used; and the statistics of the simulated control arm were stable 177 across all bootstrap simulation runs, which suggests that using RWD we can robustly simulate the 178 "standard of care" control arm. In the two-arm comparative effectiveness simulations, we used 179 propensity score matching on baseline characteristics to simulate the randomization process. It has 180 been demonstrated that propensity score matching could reduce bias in the estimate of the treatment 181 response,^{12–15} and in our study, we successfully simulated two groups of patients that have similar

182 age, sex, race, and CCI distributions using propensity score matching. However, the SAE outcomes 183 in the simulated trial were still different from the original trial for various reasons (1) the original 184 trial was conducted in research settings, while RWD data reflect patients the real-world clinical 185 settings. The total time at risk for SAEs in our simulated cohort may be longer than the original trial, 186 because in clinical trials, patients may withdraw from the study once experiencing an SAE, while 187 patients in real-world setting may not. This is demonstrated by our simulation of dropouts, which 188 achieved smaller number of SAEs and closer results to the original trial; (2) sample size issue, where 189 23mg donepezil has not been the standard-of-care for AD in the real-world, leading to considerably 190 fewer patients in the 23mg arm. For the two-arm simulation, we conducted a post-hoc power 191 analysis with the SAE rates and mean SAE. Assuming a significant level at 0.05, a 65% power were 192 achieved; and (3) although propensity score matching derived two simulation arms that are 193 comparable, we were unable to compare it directly to the study population in the original trials as 194 the data for calculating propensity scores were not available from the original trial. For example, the 195 switching to the 23mg treatment after receiving at least 3 months of the 10mg does not occur at 196 random in a real-world setting, but based on clinical guidelines; and indeed, we found that patients 197 in the 23mg arm have a longer history of diagnosis (i.e., mean of days between first diagnosis and 198 first prescription in 23mg arm is 398 days vs. 128 days in the 10mg arm). Therefore, in our two-arm 199 simulation, there may be residue selection bias causing a difference between the two populations; 200 Nevertheless, this is an issue of using observational data in general; even though we can simulate 201 randomization, e.g., through propensity score matching; but trial simulations cannot replace RCTs. 202 In addition, there are still gaps, especially data gaps in RWD, that also contributed to the differences 203 between our simulation results and the original trial results. Future studies are warranted to 204 identify strategies to fill these gaps.

205

206 While simulating the original AD trial followed the study protocol in **Table 1**, we found it is difficult 207 to replicate all the eligibility criteria of the original trial. Out of the 36 eligibility criteria, only 25 of 208 them were computable or partially computable against the OneFlorida data. Since these criteria 209 were used to weed out patients who are unlikely to complete the protocol (e.g., due to safety 210 concerns), ignoring some of the criteria (not computable eligibility criteria) could potentially explain 211 some of the increases either in the mean SAE or the SAE rates. One strategy for future simulation 212 studies is to classify each of the eligibility criteria based on their clinical importance to the simulation 213 study and the endpoints (i.e., effectiveness or safety) related with the criterion. By doing so, we can 214 adjust the eligibility criteria and customize the simulation based on questions of interest. For 215 example, efficacy-related criteria may have very small impact on a trial that is focused on examining 216 safety and toxicity; so simulations of such trials can loosen the restrictions on efficacy-related 217 criteria. Nevertheless, as all the patients we identified in the OneFlorida data have taken the study 218 drugs of interest (i.e., different dosages of donepezil), they should all have been eligible to the 219 original trial in an ideal world, where the trial participants truly reflect target population (i.e., higher 220 trial generalizability).

221

Our findings are consistent with previous literature on clinical trial generalizability.¹⁶⁻¹⁹ More SAEs were observed in real-world settings. In our data, the overall number of patients who had SAEs and the average number of SAEs per patient were (1) the highest in the effective target population (i.e., patients who took donepezil for AD), which is the population who actually used the medication in real-world settings, but also (2) higher in the study population—patients who used donepezil for AD and also met the original trial's eligibility criteria. Some of the differences may be due to the

228	incomputable eligibility criteria (e.g., general physical health deterioration) that we cannot account
229	for, but it is also possible that the original trial samples did not adequately reflect the TP and thus
230	there might be treatment effect heterogeneity across patient subgroups, not captured by the original
231	trial. In the two-arm simulations, large variances were observed, especially when the matched
232	sample size was small. This may also indicate the heterogeneous treatment effects of donepezil
233	when applied to different patient subgroups in real-world settings.

234

235 Our study demonstrated the feasibility of trial simulation using RWD, especially when simulating 236 external standard-of-care control arms. Our one-arm simulation provided stable and robust 237 estimates and sufficient sample sizes to compare with the original trial's control arm. The SAE rates 238 observed in the simulated control arm with proportional sampling were very close to what was 239 reported in the original trial. The mean SAE per patient and SAE event rates, however, were larger 240 in the simulated control arms, which suggested that, in a real-world setting, the patients who 241 experienced SAEs tend to have more occurrences of SAEs. On the other hand, the two-arm 242 simulation, although it provided insights, was not entirely successful. Although the randomization 243 process was effectively simulated by using propensity score matching, the outcome measures were 244 very different from the original trial. The reasons for the differences could be multi-fold (e.g., 245 research setting vs. real-world clinical setting, difference in sample size, overly restrictive eligibility 246 criteria that limits the generalizability of the original trial), but cannot be explored due to limited 247 data reported by the original trial (i.e., no patient-level data is available). When we simulated 248 dropouts using information from the original trial, we observed similar SAE rates and mean SAE 249 compared to the original trial in both random dropout or AE-based dropout strategies, especially in 250 the control arms. This suggests that the additional simulation scenarios have led to results more

comparable to the cohorts in the original trial. However, due to the small sample size in the 23mg arm, we were only able to simulate random dropout for the two-arm simulation, and the SAE measurements did not change much comparing to the simulations without dropout. Future studies with sufficient sample sizes could conduct more sophisticated analysis based on treatment delay and adherence.

256

257 Compared with trial emulation, which focus on making the target trial explicitly characterized with 258 a defined protocol, our approach takes the advantage of having observational RWD, where different 259 trial protocols (i.e., simulation scenarios) with different study designs can be readily tested. For 260 example, in our current study, there are several potential simulation points that can be further 261 tuned. First, the sample size of each arm can be adjusted. In the one arm simulation (i.e., the control 262 arm of 10mg donepezil), we choose the same sample size as the original trial, but it can be adjusted 263 to increase power. Second, the eligibility criteria of selecting study population could also be 264 adjusted to test different hypotheses. For example, we can adjust the eligibility criteria in the trial 265 simulation process to assess how the original trial results may be generalized into real-world target 266 population, and provide insights on how to balance internal validity while retaining good external 267 validity.^{17,20} Third, different scenarios of dropout may be simulated. The dropout rate and timing 268 can be varied, so that it can be used to simulate different patient population. Further, we can also 269 explore whether other dropout reasons such as lack of recovery and lack of access to care can be 270 simulated based on real-world data. Many other potential simulation scenarios can be tested such 271 as varying the 3-month lead time for switching from 10mg to 23mg. In this current work, as our 272 main goal was to establish the feasibility of such simulation approach, we only conducted limited 273 number of major simulation scenarios (e.g., we used two different sampling scenarios using

274 different intervention arm vs. control arm ratios). In future work, informed by literature, we shall 275 systematically simulate the different trial design scenarios, which can (1) provide critical information 276 on the comparative effectiveness of the interventions in real-world settings, but also (2) better inform 277 the study designs of future clinical trials. Last but not least, the one-arm simulation is as important 278 as the two-arm simulation, even though it does not provide comparative effectiveness results of the 279 intervention. In addition to informing future design of control arms, one-arm simulation allows us 280 to utilize readily available RWD of patients taking the standard-of-care (SOC) to determine SOC's 281 treatment effectiveness and safety profile and consider different study protocols and scenarios. The 282 demonstrated feasibility of one-arm simulation is a building block towards the potential of using 283 RWD to generate synthetic and external controls for clinical trials, leading to significant cost 284 savings.²¹ Nevertheless, other issues with RWD such as its data quality (e.g. missing key measures 285 of endpoints) and the inherent biases exist in observational data, warrant further investigations. 286

287 There are some other limitations in this study. First, we only looked at one original trial for one 288 medication (i.e., donepezil). Simulations on different drugs and diseases may have different results. 289 Second, the population who took the 23mg form in our data is very small (even though the overall 290 OneFlorida population is large with more than 15 million patients), where we only identified 38 291 patients who took the 23mg donepezil and met the eligibility criteria of the original trial. The 23mg 292 donepezil form was approved by the FDA in 2012, so it is still a relatively new drug on the market, 293 and following its approval, the clinical utility of the 23mg form was called into question because of 294 its limited effectiveness and higher rates of adverse events.²² The current practice of using the 295 donepezil 23mg form is reserved for AD patients who have been on stable donepezil 10 mg form for 296 at least 3–6 months with no significant improvement,^{31,32} which limited its use in real-world clinical

297 practice. In addition, patients who switched to the 23mg treatment may have different 298 characteristics in characteristics that we did not account for in this analysis. Third, we found some 299 of the SAEs (e.g., abnormal behavior, presyncope) reported in the trial's results cannot be mapped to 300 any AE terms in CTCAE, and the definitions of AEs in the original trial were unavailable, which 301 increased the difficulty of accurately accounting for all SAEs. Further, even though trials' SAEs 302 reported in ClinicalTrials.gov largely follow the Medical Dictionary for Regulatory Activities 303 Terminology (MedDRA), not all reported SAEs were correctly defined in the trial results. For 304 example, we found "Back pain" and "Fall" were defined as SAEs in the original AD trial we modeled. 305 However, in CTCAE, there is no corresponding category 4 or 5 definition for them. More effort is 306 needed to consistently model SAEs reported in clinical trials. Finally, because of data limitations, we 307 were not able to assess the effectiveness of AD treatment (e.g., AD end points such as Mini-Mental 308 State Examination and Severe Impairment Battery are not readily available in structure EHR data, 309 but may exist in clinical narratives). Thus, we only examined safety outcomes in our current study. 310 This may also contribute to the different results we obtained from our simulation compared with 311 results from the original trial as the original trial was designed and powered with primary efficacy-312 based outcomes. Future studies that explore the use of advanced natural language processing (NLP) 313 methods to extract these endpoint measurements from clinical notes will be important. Further, 314 variables extracted from clinical notes with NLP could also be used to render some of the 315 incomputable eligibility criteria computable. 316 317 In conclusion, in this study, we investigated the feasibility of using the existing patient records to

simulate clinical trials using an Alzheimer's disease trial (i.e. NCT00478205) as the use case. We

319 examined two main simulation scenarios: (1) a one-arm simulation: simulating the standard-of-care

320 arm that can serve as an external control arm; and (2) a two-arm simulation: simulating both 321 intervention and control arms with proper patient matching algorithms for comparative 322 effectiveness analysis. We have also considered a number of different simulation parameters such 323 sampling strategies, matching approaches, and dropout scenarios. In the case study, our simulation 324 can robustly simulate "standard of care" control arms (i.e. the 10mg donepezil arm) in terms of safety 325 evaluation. However, trial simulation using RWD may be limited by the availability of RWD that 326 matches the target trials of interest and may not yield reliable and consistent results if the sample 327 sizes of the interventions of interest (i.e. we found few patients were prescribed the 23mg donepezil) 328 are limited from the real-world databases. Further investigations on this topic are warranted, 329 especially how to address the data quality issues (e.g. using NLP to extract more complete patient 330 information) and reduce inherent biases (e.g. more advanced matching methods to tackle the 331 problems of high dimensionality, nonlinear/nonparallel treatment assignment, and other complex 332 confounding situations²⁵) in observational RWD. Last but not least, it will also be beneficial to have 333 access more complete information (e.g. de-identified individual-level trail participant data) of the 334 target trials, so that more realistic simulation settings can be explored.

335

336 Methods

337 The target Alzheimer's disease (AD) trial and its characteristics

Although there is no cure for AD yet, the U.S. FDA approved two classes of medications: (1)

339 cholinesterase inhibitors, and (2) memantine, to treat the symptoms of dementia. Donepezil

- 340 (Aricept®), a cholinesterase inhibitor, was the most widely tested AD drug and approved for all
- 341 stages of AD. The target trial NCT00478205²⁶ is a Phase III double-blind, double-dummy, parallel-
- 342 group comparison of 23 mg donepezil sustained release (SR) with the 10 mg donepezil immediate

343	release (IR) formulation (marketed as the standard-of-care) in patients with moderate to severe
344	Alzheimer's disease. Patients who have been taking 10 mg IR (or a bioequivalent generic) for at least
345	3 months prior to screening were recruited. The original trial consisted of 24 weeks of daily
346	administration of study medication, with clinic visits at screening, baseline, 3 weeks (safety only), 6
347	weeks, 12 weeks, 18 weeks, and 24 weeks or early termination. Patients received either 10 mg
348	donepezil IR in combination with the placebo corresponding to 23 mg donepezil SR, or 23 mg
349	donepezil SR in combination with the placebo corresponding to 10 mg donepezil IR. A total of 471
350	and 963 patients were enrolled from approximately 200 global sites (Asia, Oceania, Europe, India,
351	Israel, North America, South Africa, and South America). The results of the original trial yielded
352	that donepezil 23 mg/d was associated with greater benefits in cognition compared with donepezil
353	10 mg/d and led to the FDA approval of the new 23 mg dose form for treatment of AD in 2010,27
354	despite the debate on whether the 2.2 point of cognition improvement (on a 100 point scale) over the
355	10 mg dose form is sufficient. ^{22,28}
356	
357	In our simulation, we followed the detailed study procedures outlined in their published article ²⁷ to
358	formulate our simulation protocol, including the treatment regimen, population eligibility, and
359	follow-up assessments for SAEs. Table 1 describes how the original trial design was followed in our
360	simulation.
361	
362	Real-world patient data (RWD) from the OneFlorida network
363	The OneFlorida data contain robust longitudinal and linked nationt-level RWD of ~15 million (>60%)

The OneFlorida data contain robust longitudinal and linked patient-level RWD of ~15 million (>60%)
Floridians, including data from Medicaid claims, cancer registries, vital statistics, and EHRs from its
clinical partners. As one of the PCORI-funded clinical research networks in the national PCORnet,

366	OneFlorida includes 12 healthcare organizations that provide care through 4,100 physicians, 914
367	clinical practices, and 22 hospitals, covering all 67 Florida counties. The OneFlorida data is a Health
368	Insurance Portability and Accountability Act (HIPAA) limited data set (i.e., dates are not shifted and
369	location data are available) that contains detailed patient characteristics and clinical variables,
370	including demographics, encounters, diagnoses, procedures, vitals, medications, and labs. ²⁹ We
371	focused on the structured data immediately available to us formatted according to the PCORnet
372	common data model (PCORnet CDM). ³⁰
373	
374	Cohort identification: the target population, the study population, and the trial not eligible
375	population
376	From the OneFlorida data, we identified three populations: the target population (TP), the study
377	population (SP), and the trial not eligible population (NEP) for the target trial following the process
378	shown in Figure 1 Panel a, and the relationship between these populations are displayed in Figure 1
379	Panel b . The <i>true</i> target population should be those that will benefit from the drug, thus, should be
380	broader as patients with AD in general. However, as patients who were not treated with donepezil
381	in real-world would not have any safety or effectiveness data of the drug in RWD, the effective
382	target population of interest is a constrained subset-patients who (1) had the disease of interest
383	(i.e., AD), and (2) had used the study drug (i.e., donepezil) for a specific time period according to the
384	study protocol. The 10mg donepezil is only in immediate release (IR) form while the 23mg
385	donepezil is exclusively in sustained release (SR) form, so we used the corresponding RxNorm
386	concept unique identifier (RXCUI) and the National Drug Code (NDC) to identify the two groups
387	(i.e., 10mg vs. 23mg) of patients in our data. ^{31,32} We then identified the study population (i.e.,

patients who met both the TP criteria and the trial eligibility criteria) and trial not eligible population

389 (i.e., patients who meet the TP criteria but do not meet the trial eligibility criteria) by applying the 390 eligibility criteria of the target trial to the TP. To do so, we analyzed the target trial's eligibility 391 criteria and determined the computability of each criterion. A criterion is computable when its 392 required data elements are available and clearly defined in the target patient database (i.e., the 393 OneFlorida data in our study). Then, we manually translated the computable criteria into database 394 gueries against the OneFlorida database. We assumed that all patients met the non-computable 395 criteria (e.g., "written informed consent"), which is a limitation of our study. The full list of eligibility 396 criteria and their computability are listed in the **Supplementary Table 2**. We first decomposed each 397 criterion (e.g., "Patients with dementia complicated by other organic disease or Alzheimer's disease with 398 delirium") into smaller study traits (e.g., "dementia complicated by other organic disease" and 399 "Alzheimer's disease with delirium"). We then checked whether each of the study trait is 400 computable based on the OneFlorida data as shown in **Supplementary Table 2**. We then used the 401 computable study traits to determine patients' eligibility. Many of the incomputable study traits are 402 not clinically relevant for our studies (e.g., "No caregiver available to meet the inclusion criteria for 403 caregivers."). Nevertheless, how computability of these study traits affect the trial simulation results 404 – a limitation of our current study – warrant further investigations in future studies. 405

406 Definition and identification of serious adverse events (SAE) from EHRs

407 The target trial used Severe Impairment Battery (SIB) and the Clinician's Interview-Based

408 Impression of Change Plus Caregiver Input scale (CIBIC+; global function rating) to assess the

- 409 efficacy of donepezil in AD patients. Because these effectiveness data are not readily available in the
- 410 structured EHR data, we focused on assessing drug safety in terms of the occurrences of SAEs. To
- 411 define an SAE, we followed the FDA³³ definition of SAEs and the Common Terminology Criteria for

412	Adverse Events (CTCAE) version 5 – a descriptive terminology for Adverse Event (AE) reporting.
413	In CTCAE, an AE is any "unfavorable and unintended sign, symptom, or disease temporally associated with
414	the use of a medical treatment or procedure that may or may not be considered related to the medical treatment
415	or procedure," and the AEs are organized based on the System Organ Class (SOC) defined in Medical
416	Dictionary for Regulatory Activities (MedDRA ³⁴). CTCAE also provides a grading scale for each AE
417	into Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe or medically significant but not
418	immediately life-threatening), Grade 4 (life-threatening consequences), and Grade 5 (death).
419	
420	We mapped each reported SAE in the trial results section of the target trial NCT00478205 on
421	ClinicalTrails.gov at https://www.clinicaltrials.gov/ct2/show/results/NCT00478205 to the CTCAE
422	term and identified the severity based on the CTCAE grading scale. We considered an AE as SAE if
423	it meets the criteria for Grade 3/4 (results in hospitalization), and Grade 5 (death). As shown in
424	Figure 2, to count as a SAE related to donepezil, the SAE event has to occur within 24 weeks after
425	the first donepezil prescription (which is the same follow-up period as the original trial). Note that
426	we excluded chronic conditions that happened before the study, for example, different types of
427	cancer.
428	
429	Trial simulation
430	<i>Table 1</i> shows our design of the simulated trial corresponding to the original target trial. Based on
431	the calculation from the original trial ²⁷ , a sample size of 400 and 800 were needed for the 10mg and

432 23mg arms, respectively. We first simulated the control arm of the standard therapy (i.e., the 10 mg

433 arm of the original trial), where we have a sufficiently large sample size from the OneFlorida data.

434 We designed our simulation based on the sample size of the arm in the original trial (N=400), and

tested two different sampling approaches: (1) random sampling, and (2) proportional samplingcontrolling for race distribution.

437

438 Even though we did not find a sufficient number of patients who took 23mg donepezil in our data, 439 we still simulated both case-control arms using the same sampling strategy in the one-arm 440 simulation that yielded the closest effect sizes compared with the original trial. We explored two 441 different scenarios with different sample sizes: (1) the ratio of the number of subjects in the 23mg 442 arm to the 10mg arm was set as 1 to 1, and (2) the ratio was set as 1 to 3. Because of the limited 443 number of individuals who took the 23mg form, we can only increase the number of subjects in the 444 10mg arm in the second sample size scenario. We used propensity score matching (PSM) to 445 simulate randomization. The variables used for PSM included age, gender, race, and Charlson 446 comorbidity index (CCI, i.e., as a proxy for baseline overall health of the patient) prior to baseline. 447 Specifically, we fitted a logistic regression model using different treatment (i.e., case vs. control) as 448 the outcome variable and age, gender, race, and CCI as covariates to generate the logistic 449 probabilities of propensity scores individuals in the two comparison groups and then used the 450 nearest neighbor method to carry out the mapping process. The two arms were matched with the 451 propensity scores with a 1:1 or 1:3 ratio.

452

453 Specifically, we first used proportional sampling to extract a sample of patients for the 23mg study 454 population using the same race distribution as in the original trial, and then identified a matched 455 sample for the 10mg study population using PSM. We then calculated the SAEs in the 10mg vs. 456 23mg arms as the safety outcomes. The simulation process was performed 1,000 times with 457 bootstrap sampling with replacement, and the mean value and 95% confidence interval (CI) of each

458	bootstrap sample were calculated to generate the overall estimates. We focused on comparing the
459	average number of SAE per patient, the overall SAE rates (i.e., how many patients had SAEs), and
460	stratified the analysis by major SAE categories according to the CTCAE guideline. The effects of
461	PSM were evaluated by examining the distributions of propensity scores using jitter plot
462	(Supplementary Table 1 and Supplementary Figure 1).
463	
464	
465	
466	Data availability statement
467	OneFlorida data can be requested at https://onefloridaconsortium.org/front-door/; Since OneFlorida
468	data is a HIPAA limited data set, a data use agreement needs to be established with the OneFlorida
469	network.
470	
471	Code availability statement
472	The data processing and analysis were conducted using R version 4.0.2. The code used in this work
473	is available upon reasonable request for academic purposes.
474	
475	Acknowledgements
476	This work was supported in part by NIH grants R21AG068717, R21AG061431, and UL1TR001427.
477	The content is solely the responsibility of the authors and does not necessarily represent the official
478	views of the NIH.
479	
480	Author contributions

481	ZC	, HZ, and JB designed the initial concepts; ZC and HZ carried out the analysis; ZC, HZ, and JB	
482	wrote the initial draft of the manuscript. TM, YG, MP, ZH, WH, FW, and ES provided critical		
483	feedback and edited the manuscript.		
484			
485	Competing interests		
486	The	e authors declared there is no competing interests.	
487			
488	Ref	erences	
489	1.	Aronson, J. K. What is a clinical trial? British Journal of Clinical Pharmacology vol. 58 (John Wiley &	
490		Sons, Ltd, 2004).	
491	2.	Sertkaya, A., Wong, H. H., Jessup, A. & Beleche, T. Key cost drivers of pharmaceutical clinical	
492		trials in the United States. Clin. Trials (2016) doi:10.1177/1740774515625964.	
493	3.	Scott, T. J., O'Connor, A. C., Link, A. N. & Beaulieu, T. J. Economic analysis of opportunities to	
494		accelerate Alzheimer's disease research and development. Ann. N. Y. Acad. Sci. 1313, 17–34	
495		(2014).	
496	4.	Holford, N., Ma, S. C. & Ploeger, B. A. Clinical Trial Simulation: A Review. Clin. Pharmacol. Ther.	
497		88, 166–182 (2010).	
498	5.	Gal, J. et al. Optimizing drug development in oncology by clinical trial simulation: Why and	
499		how? Brief. Bioinform. 19, 1203–1217 (2018).	
500	6.	Romero, K. et al. The Future Is Now: Model-Based Clinical Trial Design for Alzheimer's Disease.	
501		<i>Clin. Pharmacol. Ther.</i> 97 , 210–214 (2015).	
502	7.	Hernán, M. A. & Robins, J. M. Using Big Data to Emulate a Target Trial When a Randomized	
503		Trial Is Not Available. Am. J. Epidemiol. (2016) doi:10.1093/aje/kwv254.	

504	8.	Danaei, G., Rodríguez, L. A. G., Cantero, O. F., Logan, R. & Hernán, M. A. Observational data
505		for comparative effectiveness research: An emulation of randomised trials of statins and
506		primary prevention of coronary heart disease. Stat. Methods Med. Res. (2013)
507		doi:10.1177/0962280211403603.
508	9.	Garcia-Albeniz, X., Hsu, J. & Hernan, M. A. The value of explicitly emulating a target trial when
509		using real world evidence: an application to colorectal cancer screening. Eur. J. Epidemiol. 32,
510		495–500 (2017).
511	10.	Admon, A. J. et al. Emulating a Novel Clinical Trial Using Existing Observational Data.
512		Predicting Results of the PreVent Study. Ann. Am. Thorac. Soc. 16, 998–1007 (2019).
513	11.	Zhang, H. et al. Computable Eligibility Criteria through Ontology-driven Data Access: A Case
514		Study of Hepatitis C Virus Trials. AMIA Annu. Symp. Proc. AMIA Symp. 2018, 1601–1610 (2018).
515	12.	Brookhart, M. A., Wyss, R., Layton, J. B. & Stürmer, T. Propensity Score Methods for
516		Confounding Control in Non-Experimental Research. Circ. Cardiovasc. Qual. Outcomes 6, 604-611
517		(2013).
518	13.	Dekkers, I. A. & van der Molen, A. J. Propensity Score Matching as a Substitute for Randomized
519		Controlled Trials on Acute Kidney Injury After Contrast Media Administration: A Systematic
520		Review. AJR Am. J. Roentgenol. 211, 822–826 (2018).
521	14.	Lin, J., Gamalo-Siebers, M. & Tiwari, R. Propensity score matched augmented controls in
522		randomized clinical trials: A case study. Pharm. Stat. 17, 629–647 (2018).
523	15.	Hernan, M. A. & Robins, J. M. Causal Inference: What If. (Boca Raton: Chapman & Hall/CRC,
524		2020).
525	16.	Stuart, E. A., Bradshaw, C. P. & Leaf, P. J. Assessing the generalizability of randomized trial
526		results to target populations. Prev. Sci. Off. J. Soc. Prev. Res. 16, 475–485 (2015).

- 527 17. He, Z. et al. Comparing and Contrasting A Priori and A Posteriori Generalizability Assessment
- of Clinical Trials on Type 2 Diabetes Mellitus. *AMIA Annu. Symp. Proc. AMIA Symp.* 2017, 849–
 858 (2017).
- 530 18. Shrimanker, R., Beasley, R. & Kearns, C. Letting the right one in: evaluating the generalisability
- 531 of clinical trials. *Eur. Respir. J.* **52**, (2018).
- 532 19. Susukida, R., Crum, R. M., Ebnesajjad, C., Stuart, E. & Mojtabai, R. Generalizability of findings
- from randomized controlled trials: Application to the National Institute of Drug Abuse Clinical
- 534 Trials Network. *Addiction* (2017) doi:10.1111/add.13789.
- 535 20. Li, Q. et al. Assessing the Validity of a a priori Patient-Trial Generalizability Score using Real-
- 536 world Data from a Large Clinical Data Research Network: A Colorectal Cancer Clinical Trial

537 Case Study. AMIA. Annu. Symp. Proc. 2019, 1101–1110 (2020).

538 21. Thorlund, K., Dron, L., Park, J. J. H. & Mills, E. J. Synthetic and External Controls in Clinical

539 Trials – A Primer for Researchers. *Clin. Epidemiol.* **12**, 457–467 (2020).

- 540 22. Schwartz, L. M. & Woloshin, S. How the FDA forgot the evidence: the case of donepezil 23 mg.
 541 *BMJ* 344, (2012).
- 542 23. Deardorff, W. J., Feen, E. & Grossberg, G. T. The Use of Cholinesterase Inhibitors Across All
 543 Stages of Alzheimer's Disease. *Drugs Aging* 32, 537–547 (2015).
- 544 24. Cummings, J. L. et al. High-dose donepezil (23 mg/day) for the treatment of moderate and
- severe Alzheimer's disease: drug profile and clinical guidelines. *CNS Neurosci. Ther.* **19**, 294–301

546 (2013).

- 547 25. Ghosh, S., Bian, J., Guo, Y. & Prosperi, M. Deep propensity network using a sparse autoencoder
- for estimation of treatment effects. J. Am. Med. Inform. Assoc. ocaa346 (2021)
- 549 doi:10.1093/jamia/ocaa346.

- 550 26. Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release
- 551 (IR) in Patients With Moderate to Severe Alzheimer's Disease Full Text View -
- 552 ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00478205.
- 553 27. Farlow, M. R. et al. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose
- 554 (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized,
- 555 double-blind study. *Clin. Ther.* **32**, 1234–1251 (2010).
- 556 28. English, C. Donepezil 23 mg: Is it more advantageous compared to the original? *Ment. Health*
- 557 *Clin.* **1**, 272–273 (2012).
- 558 29. Shenkman, E. *et al.* OneFlorida Clinical Research Consortium: Linking a Clinical and
- 559 Translational Science Institute With a Community-Based Distributive Medical Education Model.
- 560 Acad. Med. J. Assoc. Am. Med. Coll. 93, 451–455 (2018).
- 561 30. PCORnet. PCORnet Common Data Model v5.1 Specification (12 Sep 2019).
- 562 https://pcornet.org/data-driven-common-model/ (2019).
- 563 31. Gomolin, I. H., Smith, C. & Jeitner, T. M. Donepezil Dosing Strategies: Pharmacokinetic
- 564 Considerations. J. Am. Med. Dir. Assoc. 12, 606–608 (2011).
- 565 32. Lee, J.-H., Jeong, S.-K., Kim, B. C., Park, K. W. & Dash, A. Donepezil across the spectrum of
- 566 Alzheimer's disease: dose optimization and clinical relevance. *Acta Neurol. Scand.* **131**, 259–267
- 567 (2015).
- 568 33. CFR Code of Federal Regulations Title 21.
- 569 https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=314.80.
- 570 34. Welcome to MedDRA | MedDRA. https://www.meddra.org/.

572 FIGURE LEGEND

- 573 **Figure 1.** The cohort identification process for the target, study, and trial not eligible populations.
- 574 Figure 2. Follow-up window for serious adverse events (SAEs) related to treating Alzheimer's
- 575 disease with donepezil.
- 576

Component	Target trial (NCT00478205)	Simulated trial	
1	Assess the safety and	Assess whether the simulated trial can generate	
Aim	effectiveness of 23mg SR	similar results to the "real" trial in terms of its	
	compared to 10 mg IR	safety profile	
Eligibility	36 eligibility criteria	25 are computable or partially computable	
		One-arm simulation of the 10 mg control arm using random sampling and proportional sampling with the same sample size as the original trial.	
Treatment	Randomized allocation of 23mg		
strategies	:10 mg ratio is 2:1	Two-arm simulations considering different case-	
		to-control ratios. Propensity score matching was performed on the following baseline covariates: sex, race, age, and Charlson comorbidity index (CCI).	
Sampling strategies	N/A	Bootstrap with replacement was repeated 1,000 times to randomly generate the sample population, and mean value and 95% confidence interval were reported.	
Follow-up	The outcomes were measured from the first dose to 24 weeks after the first dose.		
Outcome	SAE and cognition function measures	SAE ¹	
Statistical analysis			
¹ SAE: Serious Adverse Events			

Table 1. Overall study design of the simulated trial in comparison with the original trial.

	23mg Arm				10mg Arm	m			
	Original	Overall	Overall	Overall	Original	Overall	Overall	Overall	
	Trial ¹	TP^2	SP ³	NEP ⁴	Trial	TP^5	SP^6	NEP ⁷	
# of Subject	963	90	38	52	471	2,048	782	1,266	
Age Mean (SD)	73.9	74.3	73.3	81.6	73.8	73.4	74.2	77.1	
-	(8.53)	(9.01)	(9.01)	(12.37)	(8.56)	(11.0)	(9.67)	(11.8)	
Gender									
Male	356	24	10	14	177	727	234	493	
	(37.0%)	(26.7%)	(26.3%)	(26.9%)	(37.6%)	(35.5%)	(29.9%)	(38.9%)	
Female	607	66	28	38	294	1321	548	773	
	(63.0%)	(73.3%)	(73.7%)	(73.1%)	(62.4%)	(64.5%)	(70.1%)	(61.1%)	
Race ^e									
White	708	63	25	38	346	829	280	549	
	(73.5%)	(70.0%)	(65.8%)	(73.1%)	(73.5%)	(40.5%)	(35.8%)	(43.4%)	
Asian/Pacific	161	0	0	0	87	22	11	11	
	(16.7%)	(0%)	(0%)	(0%)	(18.5%)	(1.1%)	(1.4%)	(0.9%)	
Hispanic	67	15	4	11	26	440	192	248	
	(7.0%)	(16.7%)	(10.5%)	(21.2%)	(5.5%)	(21.5%)	(24.6%)	(19.6%)	
Black	22	11	4	7	9	380	126	254	
	(2.3%)	(12.2%)	(10.5%)	(13.5%)	(1.9%)	(18.6%)	(16.1%)	(20.1%)	
Other	5	1	5	7	3	377	173	204	
	(0.5%)	(1.1%)	(13.2%)	(13.5%)	(0.6%)	(18.4%)	(22.1%)	(16.1%)	
CCI ^f	N/A	1.54	1.32	1.53	N/A	2.36	1.64	2.36	
Mean SAE ^g	0.15	1.89	0.92	2.60	0.14	1.68	0.64	2.59	
# of patients with	45 (9.6%)	20	4 (10.5%)	16	80 (8.3%)	573	121	452	
$\geq 1 \text{ SAE}$		(22.2%)		(30.7%)		(28.0%)	(15.5%)	(35.7%)	

Table 2. Population characteristics and SAE statistics of the target trial vs. TP, SP, and NEP from OneFlorida.

¹Reported in the original trial on ClinicalTrials.gov

²TP: Target population—patients who (1) had the disease of interest (i.e., AD), and (2) had used the study drug (i.e. donepezil) for a specific time period according to the study protocol.

³SP: Study population—patients in the TP who met the computable eligibility criteria of the original trial.

⁴NEP: Trial not eligible population—patients in the TP who did NOT meet the eligibility criteria of the original trial.

⁵The original trial reported Hispanic as a race, thus, we followed the same convention to make sure the results are comparable even though race and ethnicity are two different fields in OneFlorida.

⁶Charlson Comorbidity Index.

⁷Mean SAE: average number of SAEs per patient.

	Original control arm	Simulated control			
	Original control arm	Random sampling	Proportional sampling		
Number of subjects	471	400	240		
Mean age	73.8	78.5±0.1	78.2±0.1		
Gender					
Female	62.4%	70.1%±0.1%	66.1%±0.1%		
Male	37.6%	29.9%±0.1%	33.9%±0.1%		
Race					
White	73.5%	28.1%±0.1%	73.3%±0.1%		
Black	1.9%	16.0%±0.1%	2.1%±0.1%		
Hispanic	5.5%	24.5%±0.1%	5.4%±0.1%		
Asian & Other	19.1%	31.3%±0.2%	19.2%±0.1%		
SAE ¹ rates (patient with ≥ 1 SAE)	8.3%	15.5%±0.1%	8.9%±0.1%		
Mean SAE (average SAE per patient)	0.14	0.64±0.01	0.48±0.01		
SAE event rates by category					
Blood and lymphatic system disorders	0/471 (0.00%)	4.9%±0.1%	3.2%±0.1%		
Cardiac disorders	6/471 (1.23%)	2.9%±0.1%	2.0%±0.1%		
Eye disorders	1/471 (0.2%)	0	0		
Gastrointestinal disorders	2/471 (0.4%)	7.0%±0.1%	5.9%±0.1%		
General disorders	3/471 (0.6%)	1.7%±0.1%	1.1%±0.1%		
Hepatobiliary disorders	2/471 (0.4%)	1.2%±0.1%	1.9%±0.1%		
Infections and infestations	9/471 (1.9%)	5.8%±0.1%	4.7%±0.1%		
Injury, poisoning and procedural complications	8/471 (1.7%)	3.2%±0.1%	3.0%±0.1%		
Musculoskeletal and connective tissue disorders	2/471 (0.4%)	0.7%±0.1%	0.8%±0.1%		
Neoplasms benign, malignant and unspecified	2/471 (0.4%)	0	0		
Nervous system disorders	15/471 (3.3%)	6.6%±0.1%	4.8%±0.2%		
Psychiatric disorders	11/471 (2.3%)	3.3%±0.1%	2.5%±0.1%		
Renal and urinary disorders	2/471 (0.4%)	4.2%±0.1%	1.9%±0.1%		
Reproductive system and breast disorders	0	0	0		

Table 3. One-arm simulation results for the 10mg control arm.

Respiratory, thoracic and mediastinal disorders	1/471 (0.2%)	1.0%±0.1%	1.4%±0.1%				
Vascular disorders	1/471 (0.2%)	0.7%±0.1%	0.3%±0.1%				
¹ SAE: severe adverse events							

	1	al trial	Simulated trial				
			Proportional	1:1 matching	Proportional 1:3 matching		
	23 mg	10mg	23mg	10mg	23mg	10mg	
Number of subjects	963	471	24	24	24	72	
Mean age	73.9	73.8	79.2±0.1	79.5±0.2	79.1±0.1	79.4±0.2	
Gender							
Female	63.0%	62.4%	70.2%±0.6%	69.8%±0.7%	70.4%±0.6%	69.4%±0.6%	
Male	37.0%	37.6%	29.8%±0.6%	30.2%±0.7%	29.6%±0.6%	30.6%±0.6%	
Race							
White	73.5%	73.5%	70.8%±0.1%	70.3%±0.1%	70.8%±0.1%	70.2%±0.1%	
Hispanic	7.0%	5.5%	8.3%±0.1%	7.9%±0.3%	8.3%±0.1%	8.1%±0.3%	
Black	2.3%	1.9%	4.2%±0.1%	4.2%±0.3%	4.2%±0.1%	4.2%±0.2%	
Asian & Other	17.2%	0.6%	16.7%±0.1%	17.6%±0.3%	16.7%±0.1%	17.6%±0.3%	
Charlson Comorbidity Index	n	/a	1.25±0.02	1.17±0.03	1.25±0.02	1.23±0.02	
SAE ¹ rates (patient with ≥ 1 SAE)	9.6%	8.3%	9.8%±0.4%	12.6%±0.4%	9.4%±0.2%	11.2%±0.2%	
Mean SAE (average SAE per patient)	0.15	0.14	0.99±0.05	0.46±0.05	0.99±0.05	0.47±0.02	
SAE Event rates by category							
Blood and lymphatic system disorders	0.2%	0	14.5%±0.9%	0.052±0.004	0.146±0.10	0.042±0.001	
Cardiac disorders	1.9%	1.3%	6.7%±0.3%	0.012±0.001	0.068±0.005	0.016±0.015	
Eye disorders	0	0.2%	0	0	0	0	
Gastrointestinal disorders	2.4%	0.4%	0	0.082±0.004	0	0.059±0.057	
General disorders	0.6%	0.6%	1.1%±0.1%	0.006±0.001	0.010±0.001	0.008±0.001	
Hepatobiliary disorders	0.5%	0.4%	0	0.007±0.002	0	0.009±0.001	
Infections and infestations	1.3%	1.9%	20.1%±0.1%	0.026±0.002	0.199±0.010	0.037±0.002	
Injury, poisoning and procedural complications	2.5%	1.9%	0	0.014±0.003	0	0.021±0.004	
Musculoskeletal and connective tissue disorders	0.3%	0.4%	0	0.019±0.001	0	0.013±0.001	
Neoplasms benign, malignant and unspecified	1.5%	3.2%	0	0	0	0	
Nervous system disorders	1.5%	3.2%	9.8%±0.3%	0.039±0.002	0.094±0.003	0.042±0.002	
Psychiatric disorders	1.1%	2.3%	2.0%±0.5%	0.019±0.002	0.019±0.001	0.023±0.001	
Renal and urinary disorders	0.4%	0.004	27.9%±1.8%	0.011±0.002	0.281±0.018	0.016±0.001	

Table 4. Results of the two-arm simulation for proportional 1:1 and 1:3 matching.

Reproductive system and breast disorders	0.1%	0	0	0	0	0
Respiratory, thoracic and mediastinal disorders	0.1%	0.2%	0	0.011±0.001	0	0.014±0.007
Vascular disorders	0.5%	0.2%	0	0.003±0.001	0	0.003±0.001
¹ SAE: severe adverse events						



